---
layout: default
title: Apis Mellifera Apocynum Cannabinum Root Arsenic Tr
parent: 僅模型預測 (L5)
nav_order: 342
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Apocynum Cannabinum Root Arsenic Tr
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Homeopathic Cardiac Combination (8-Ingredient): TxGNN Evaluation Not Feasible

## One-Sentence Summary

This submission involves an 8-ingredient homeopathic combination product — including Apis mellifera, Digitalis, Arsenic Trioxide, Strophanthus hispidus, and four other botanical/mineral agents — with classical cardiovascular/edema indications in homeopathic medicine.
The TxGNN model **could not generate any drug repurposing predictions** for this combination, as the multi-ingredient formulation could not be mapped to a single DrugBank entry.
There is currently **no clinical trial or published literature** associated with this specific combination under the TxGNN pipeline, and **no market authorisation** exists in the United States.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory approval records found) |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (pipeline could not process multi-ingredient input) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this submission, so a standard mechanistic rationale cannot be provided. The following explains the structural limitations of the current pipeline for this candidate.

This formulation is a classical **homeopathic multi-ingredient combination** comprising agents traditionally used in cardiovascular medicine: Digitalis (foxglove, cardiac glycoside source), Strophanthus hispidus (ouabain precursor), and Apocynum cannabinum (cardiac glycoside-containing plant) are all historically used for heart failure and oedema. Sambucus nigra (elderflower) and Apis mellifera (bee venom) are used in homeopathy for fluid retention and inflammatory conditions. Lycopodium clavatum and Toxicodendron pubescens are classic polychrest homeopathic remedies with broad constitutional indications. Arsenic trioxide, while a conventional antineoplastic agent (APL) at pharmacological doses, is used in homeopathic medicine at extreme dilution for a different purpose.

The TxGNN pipeline is designed to process **single active pharmaceutical ingredients** with a DrugBank identifier. A compound homeopathic product with 8 ingredients — none of which have a shared DrugBank ID as a combination — cannot be processed by the current knowledge-graph or deep-learning prediction modules. The pipeline returned zero candidate indications as a direct consequence of this structural mismatch, not because the ingredients lack biological relevance.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination under the TxGNN pipeline query.

> **Note:** Individual ingredients (e.g., Arsenic Trioxide — NCT studies in AML/APL; Sambucus nigra — respiratory infection trials) may have independent evidence, but these cannot be attributed to the combination product as a whole.

---

## Literature Evidence

Currently no related literature available for this combination as an entity in the TxGNN evidence pipeline.

---

## US Market Information

This product has **no NDA or market authorisation** on record. No regulatory licences were found for this 8-ingredient combination in the United States.

---

## Safety Considerations

> ⚠️ **Important note regarding Arsenic Trioxide (ATO):** One of the eight ingredients is Arsenic Trioxide, a Schedule H / controlled antineoplastic substance at pharmacological concentrations. If this product contains ATO at any concentration above homeopathic dilution (i.e., below 12C / 24X Avogadro threshold), dedicated toxicology evaluation, QT-interval monitoring, and hepatotoxicity/myelosuppression risk assessment are mandatory before any clinical use.

All other safety data (warnings, contraindications, drug–drug interactions) returned no records for this combination. Please refer to the individual ingredient package inserts for safety information on each component.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot process multi-ingredient homeopathic combinations, returning zero predictions; combined with the complete absence of US market authorisation and no retrievable safety data for the combination, there is no actionable evidence base to proceed.

**To proceed, the following is needed:**

- **Pipeline re-engineering:** Determine which single ingredient(s) are the primary active agents and run each through the TxGNN pipeline independently (particularly Arsenic Trioxide, which has a DrugBank ID and known MOA in APL)
- **Regulatory classification:** Clarify whether this product is regulated as a homeopathic drug, dietary supplement, or conventional drug in the target jurisdiction — this determines which safety standards apply
- **ATO concentration disclosure:** Confirm the dilution factor of Arsenic Trioxide in the formulation; if above pharmacological threshold, a full oncology-grade safety review is required before any indication expansion
- **MOA data:** Obtain mechanism of action documentation for each ingredient from DrugBank and published pharmacology literature
- **Safety data:** Download and parse individual ingredient package inserts (FDA or TFDA) to populate warnings, contraindications, and DDI profiles
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

